Agile Therapeutics, Inc. Sustainability Profile
Agile Therapeutics, Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative contraceptive solutions for women. Founded in 2007, Agile has made significant strides in the women's health sector, particularly with its flagship product, Twirla, a transdermal contraceptive patch that offers a unique, convenient alternative to traditional birth control methods. With a commitment to addressing unmet needs in reproductive health, Agile Therapeutics has positioned itself as a leader in the industry, emphasising patient-centric solutions. The company operates primarily in the US market, where it continues to expand its reach and influence. Agile's dedication to research and development, coupled with its strategic partnerships, underscores its role as a key player in advancing women's health care.
DitchCarbon Score
How does Agile Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Agile Therapeutics, Inc.'s score of 23 is lower than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Agile Therapeutics, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. The company is a current subsidiary of Grupo INSUD, which may influence its climate commitments and reporting practices. Despite the lack of direct emissions data, Agile Therapeutics is part of a corporate family that may have broader sustainability initiatives. However, no specific reduction targets or climate pledges have been documented for Agile Therapeutics, nor are there any commitments to the Science Based Targets initiative (SBTi) or other industry-standard climate frameworks. As a subsidiary, Agile Therapeutics may align its environmental strategies with those of Grupo INSUD, but specific details on emissions reduction initiatives or targets are not available. The company’s commitment to addressing climate change remains unclear without concrete data or defined goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | |
|---|---|---|
| Scope 1 | 915,000 | 000,000 |
| Scope 2 | 471,000 | 000,000 |
| Scope 3 | 700,000 | 000,000 |
How Carbon Intensive is Agile Therapeutics, Inc.'s Industry?
How Carbon Intensive is Agile Therapeutics, Inc.'s Location?
Agile Therapeutics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Agile Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
